As Vertex Pharmaceuticals reels from a painful trial readout for its pain candidate suzetrigine, the Boston biotech has ...

Vertex currently markets four cystic fibrosis (CF) products — Trikafta/Kaftrio, Symdeko (marketed as Symkevi in Europe), Orkambi and Kalydeco. Revenues in fourth-quarter 2023 are likely to have ...

Vertex Earnings: Robust Sales of Trikafta/Kaftrio Support Long-Term Growth and Diverse Pipeline Narrow-moat Vertex delivered solid third-quarter results, highlighted by a 12% increase in product ...

NHS England has agreed a deal with Vertex for its three-drug cystic fibrosis therapy Kaftrio, just days after the EMA’s human medicines committee recommended approval of the drug. The deal means ...

Nearly 93% of the company's sales come from its cystic fibrosis (CF) drug Trikafta/Kaftrio -- for now. The big biotech company is usually highly profitable. For example, Vertex reported earnings ...

which showed that treatment with once-daily Alyftrek enhanced patient benefit compared to Vertex’s blockbuster CF drug Trikafta (Kaftrio in Europe), which is required to be administered twice daily.

Total revenues rose 12% year over year, primarily driven by higher sales of Trikafta/Kaftrio (marketed as Kaftrio in Europe) in younger age groups. The company currently markets four CF products ...

Kaftrio will be available in the coming weeks for patients Cystic fibrosis patients in Northern Ireland will be able to access the drug Kaftrio for treatments through the health service. The ...

In draft guidance, National Institute for Health and Care Excellence (NICE) experts have said Kaftrio costs too much to be offered on the NHS. A four-week consultation will decide whether it ...

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) has approved the expanded use of TRIKAFTA ® (elexacaftor ...

The FDA's nod is based on late-stage data, which show that treatment with VRTX's Alyftrek enhances patient benefit compared ...